Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (361-370 of 497) with videos related to

Pageof 50
Sort By:
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolismAlexander Solms, Stefan Willmann, Isabel Reinecke, et al.
Journal of Community Psychology|May 6, 2023
School partner perspectives on the implementation of the Your Voice Your View sexual assault prevention program for high school studentsLindsay M Orchowski, Claudia Paszek, Richard M Lopez, et al.
International Journal of Cardiology|May 6, 2021
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular diseaseJonathan Sen, Andrew Tonkin, John Varigos, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolismIsabel Reinecke, Alexander Solms, Stefan Willmann, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillationLiping Zhang, Xiaoyu Yan, Keith A A Fox, et al.
Journal of Thrombosis and Haemostasis : JTH|October 3, 2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind studyC W Colwell, S D Berkowitz, B L Davidson, et al.
Stroke|July 10, 2020
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined SourceJan F Scheitz, Guillaume Pare, Lesly A Pearce, et al.
Therapeutic Advances in Cardiovascular Disease|August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndromeLiping Zhang, Xiaoyu Yan, Partha Nandy, et al.
Circulation|February 20, 2024
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PADShea E Hogan, Eike Sebastian Debus, Mark R Nehler, et al.
Annals of Internal Medicine|October 16, 2002
Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trialCharles W Francis, Bruce L Davidson, Scott D Berkowitz, et al.
Pageof 50

Showing results (361-370 of 497) with videos related to

Sort By:
Pageof 50
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolismAlexander Solms, Stefan Willmann, Isabel Reinecke, et al.
Journal of Community Psychology|May 6, 2023
School partner perspectives on the implementation of the Your Voice Your View sexual assault prevention program for high school studentsLindsay M Orchowski, Claudia Paszek, Richard M Lopez, et al.
International Journal of Cardiology|May 6, 2021
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular diseaseJonathan Sen, Andrew Tonkin, John Varigos, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolismIsabel Reinecke, Alexander Solms, Stefan Willmann, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillationLiping Zhang, Xiaoyu Yan, Keith A A Fox, et al.
Journal of Thrombosis and Haemostasis : JTH|October 3, 2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind studyC W Colwell, S D Berkowitz, B L Davidson, et al.
Stroke|July 10, 2020
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined SourceJan F Scheitz, Guillaume Pare, Lesly A Pearce, et al.
Therapeutic Advances in Cardiovascular Disease|August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndromeLiping Zhang, Xiaoyu Yan, Partha Nandy, et al.
Circulation|February 20, 2024
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PADShea E Hogan, Eike Sebastian Debus, Mark R Nehler, et al.
Annals of Internal Medicine|October 16, 2002
Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trialCharles W Francis, Bruce L Davidson, Scott D Berkowitz, et al.
Pageof 50